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Human immunodeficiency virus type 1 (HIV-1) integrase (IN) functions in cells within the context of high molecular weight preintegration
complexes (PICs). Lens epithelium-derived growth factor (LEDGF) transcriptional coactivator/p75 and hepatoma-derived growth factor related
protein 2 (HRP2) tightly bind to HIV-1 IN and stimulate its integration activity in vitro. Here, we show that each recombinant host cell factor
efficiently reconstitutes the in vitro activity of HIV-1 PICs disrupted for functional integration by pre-treatment with high concentrations of salt.
Mutational analysis reveals that both the IN-binding and DNA-binding activities of LEDGF/p75 contribute to functional PIC reconstitution. We
also investigate a role(s) for these proteins in HIV-1 infection by using short-interfering RNA. HIV-1 infection was essentially unaffected in HeLa-
P4 cells depleted for LEDGF/p75, HRP2, or both proteins. We conclude that cells knocked-out for LEDGF/p75 and/or HRP2 will be useful
genetic tools to address the roles of these host cell factors in HIV-1 replication.
D 2005 Elsevier Inc. All rights reserved.Keywords: LEDGF/p75; HRP2; HIV-1; Integration; Integrase; PIC; RNAiIntroduction
The integration of reverse transcribed HIV-1 cDNA into a
host cell chromosome is an essential step in the viral replication
cycle (Englund et al., 1995; LaFemina et al., 1992; Sakai et al.,
1993; Stevenson et al., 1990). Although purified HIV-1
integrase (IN) protein alone is sufficient to mediate simplified
integration reactions in vitro (Bushman et al., 1990; Cherepa-
nov et al., 1999; Sinha and Grandgenett, 2005; Sinha et al.,
2002), integration in cells occurs within a large, highly ordered
nucleoprotein complex termed the preintegration complex0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1989). The PIC not only provides an amenable environment for
efficient catalysis of IN 3Vprocessing and DNA strand transfer
activities, but is also expected to protect the cDNA from
degradation and facilitate its transport into the nucleus. Recent
evidence that HIV-1 preferentially integrates into actively
transcribed genes (Mitchell et al., 2004; Schroder et al.,
2002; Wu et al., 2003) has fuelled speculation that components
of the PIC may also play a role in directing the virus to active
transcription units during integration.
PICs isolated from acutely-infected cells can integrate their
endogenous cDNA into an added target DNA in vitro (Brown
et al., 1987; Farnet and Haseltine, 1990; Fujiwara and
Mizuuchi, 1988; Lee and Coffin, 1991). The precise compo-
sition of HIV-1 PICs is largely unknown and is envisaged to
change during maturation from reverse transcription within the
cytoplasm to integration within the nucleus (Fassati and Goff,6) 415 – 426
www.e
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protein R (Vpr), matrix (MA), and reverse transcriptase (RT)
proteins each associate with de novo-synthesized HIV-1 cDNA
in cell extracts (Bukrinsky et al., 1993; Heinzinger et al., 1994;
Karageorgos et al., 1993; Miller et al., 1997). A variety of
cellular proteins, including the barrier-to-autointegration factor
(BAF), high mobility group protein A1 (HMGA1), and lens
epithelium-derived growth factor (LEDGF)/p75 also co-frac-
tionate with HIV-1 PIC activity in vitro (Farnet and Bushman,
1997; Lin and Engelman, 2003; Llano et al., 2004b; Suzuki
and Craigie, 2002). Integration activity can be disrupted by
treating PICs with relatively high concentrations of salt, and
BAF and HMGA1 were each purified through their ability to
restore integration to salt-stripped retroviral PICs (Farnet and
Bushman, 1997; Lee and Craigie, 1998). Neither BAF nor
HMGA1 appears to directly bind to IN (Hindmarsh et al.,
1999; Mansharamani et al., 2003). Instead, these proteins
appear to gain access to PICs through their abilities to bind
DNA, although for HIV-1, an interaction with MA is likely to
contribute to BAF’s recruitment (Mansharamani et al., 2003).
See Engelman (2003) and Turlure et al. (2004) for reviews on
the roles of host cell factors in retroviral DNA integration.
A separate category of HIV-1 integration co-factors, typified
by LEDGF/p75, binds directly to IN (Cherepanov et al., 2003;
Emiliani et al., 2005; Llano et al., 2004b; Turlure et al., 2004).
This member of the hepatoma-derived growth factor (HDGF)
family of proteins potently stimulated the activity of recombi-
nant HIV-1 IN protein in in vitro integration assays (Cher-
epanov et al., 2003, 2004). When expressed on its own in the
absence of other HIV-1 proteins, IN localizes to cell nuclei and
LEDGF/p75 is a dominant cellular binding partner for HIV-1
IN under these conditions (Llano et al., 2004b; Maertens et al.,
2003, 2004; Vanegas et al., 2005). RNA interference (RNAi)-
mediated depletion of endogenous LEDGF/p75 redistributed
IN from the nucleus to the cytoplasm (Llano et al., 2004b;
Maertens et al., 2003). Likewise, expression of a nuclear
localization-deficient mutant of LEDGF/p75 confined HIV-1
IN to the cell cytoplasm (Maertens et al., 2004). HIV-1 IN is a
substrate for proteosomal degradation (Devroe et al., 2003;
Mulder and Muesing, 2000) and binding to LEDGF/p75
protected IN from proteolysis in human cells (Llano et al.,
2004a). In addition to HIV-1, LEDGF/p75 binds other
lentiviral [HIV-2 (Busschots et al., 2005) and feline immuno-
deficiency virus (Llano et al., 2004b)] INs but fails to bind to
either gammaretroviral Moloney murine leukemia virus
(MoMLV) (Busschots et al., 2005; Llano et al., 2004b),
alpharetroviral Rous sarcoma virus, or deltaretroviral human
T-cell leukemia virus type 2 (Busschots et al., 2005) IN.
Because lentiviruses target genes more often than do either
gamma or alpharetroviruses, LEDGF/p75 is a PIC-associated
factor that might play a particularly important role in helping
HIV-1 to locate active transcription units during integration
(see Engelman, 2005, for review).
The IN-binding domain (IBD) in LEDGF/p75, which
resides within the C-terminal region of the protein (Cherepanov
et al., 2004, 2005; Vanegas et al., 2005), is necessary although
insufficient to stimulate HIV-1 IN activity in vitro (Cherepanovet al., 2004). A functional IBD also resides in a second HDGF
family member, HDGF related protein 2 (HRP2) (Cherepanov
et al., 2004; Vanegas et al., 2005). Akin to LEDGF/p75,
purified HRP2 protein potently stimulated the in vitro
integration activities of recombinant HIV-1 IN (Cherepanov
et al., 2004). HRP2 predominantly localizes to the nucleus
(Vanegas et al., 2005) and contains a PWWP (named for a
signature amino acid sequence motif) domain that is present in
many proteins that intimately associate with chromatin (Slater
et al., 2003; Stec et al., 2000). However unlike LEDGF/p75,
HRP2 does not appear to tether HIV-1 IN to chromatin when
the viral protein is expressed from a synthetic gene (Vanegas et
al., 2005).
To extend earlier biochemical studies on the roles of these
proteins in integration, we assayed LEDGF/p75 and HRP2 for
their abilities to reconstitute the integration activity of salt-
stripped HIV-1 PICs. Each protein displayed robust activity in
this assay. Furthermore, we show by mutational analysis that
the ability of LEDGF/p75 to reconstitute activity to salt-
stripped PICs relies on the presence of both DNA-binding and
IN-binding motifs. To then assess a role for these proteins in
HIV-1 infection using a genetic approach, we utilized short-
interfering (si) RNAs to deplete either or both HDGF family
member from cells that are susceptible to HIV-1. Of note, a
previous RNAi-based study failed to reveal a role for LEDGF/
p75 in HIV-1 replication (Llano et al., 2004b). Our results
reveal normal infectivity levels in CD4 + HeLa cells reduced
for LEDGF/p75, HRP2, or both proteins. Because our
biochemical results further implicate a role(s) for these proteins
in HIV-1 integration, we propose that cells ablated for LEDGF/
p75 and/or HRP2 via genetic knockouts will be required to
unequivocally address the roles of these IN-binding proteins in
HIV-1 replication.
Results
Purified LEDGF/p75 and HRP2 efficiently restore integration
activity to salt-stripped HIV-1 PICs
PICs isolated from HIV-1-infected cells can efficiently
integrate their endogenous viral cDNA into an added target
DNA in vitro (Chen et al., 1999; Farnet and Haseltine, 1990).
Integration activity can be disrupted by incubation with
relatively high concentrations of salt, and extracts of uninfected
SupT1 T-cells reconstituted integration activity to salt-depleted
HIV-1 PICs (Chen and Engelman, 1998; Farnet and Bushman,
1997). HMGA1 and BAF were each purified based on their
ability to restore integration activity to salt-treated retroviral
PICs (Farnet and Bushman, 1997; Lee and Craigie, 1998). In
side-by-side tests, BAF displayed a greater specific activity
than HMGA1 (Chen and Engelman, 1998; Suzuki and Craigie,
2002) while RNase A, utilized in some assays as an aspecific
control, functioned similar to HMGA1 (Chen and Engelman,
1998).
Purified LEDGF/p75 and HRP2 proteins were previously
shown to stimulate the in vitro integration activity of purified
HIV-1 IN using recombinant DNA substrates that model the
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neither of these proteins was previously tested for their
potential to restore function to salt-depleted PICs. HIV-1 PICs
isolated from acutely-infected cells were assayed for integra-
tion into fX174 target DNA as previously described (Fujiwara
and Mizuuchi, 1988; Farnet and Haseltine, 1990; Chen et al.,
1999). A portion of the preparation was treated with 1.2 M KCl
on ice to strip potential co-factors essentially as previously
described (Chen and Engelman, 1998); as some PIC loss was
encountered during subsequent spin column chromatography
and ultrafiltration steps, approximately 6-fold more material
was analyzed by agarose gel electrophoresis and Southern
blotting after salt-stripping (Fig. 1, compare lanes 7 and 8 to
lanes 5 and 6). The initial PIC preparation before salt treatment
converted about 29% of its 9.7 kb HIV-1 cDNA substrate into
the 15.1 integration product (Fig. 1, compare lanes 1 and 2)
and, as previously established (Chen and Engelman, 1998;
Farnet and Bushman, 1997), salt-stripping effectively ablated
in vitro PIC function (Fig. 1, lane 4). Incubating salt-stripped
PICs with purified LEDGF/p75 protein prior to addition of
fX174 target DNA restored starting levels of HIV-1 integra-
tion activity (Fig. 1, lane 3).
We next tested other purified proteins (HRP2, BAF, and
RNase A) as well as specific LEDGF/p75 mutant proteins (see
below) alongside wild-type LEDGF/p75 to assess their
activities in the PIC reconstitution assay. To facilitate this
analysis, we employed a real-time quantitative (RQ)-PCR
assay that was recently developed to assess HIV-1 PIC activity
in vitro (Lu et al., 2005b). This assay was particularly useful
for assessing multiple protein samples, as reconstitution
activity was reproducibly detected using just 7% of the level
of salt-stripped material required for detection by Southern
blotting (200 Al versus 3 ml). Due to the noted loss of material
incurred during salt-stripping and subsequent purification
steps, integration activity was normalized to the total levelsFig. 1. Reconstitution of salt-stripped HIV-1 PIC activity with LEDGF/p75.
Lane 1, PIC integration activity prior to salt-stripping; lane 2, level of initial
HIV-1 cDNA substrate in 0.5 ml of crude cytoplasmic extract; lane 3,
reconstitution of PIC activity following addition of LEDGF/p75; lane 4, salt-
stripped PICs incubated with target DNA in the absence of LEDGF/p75. The
migration positions of unreacted substrate DNA and the covalent product of
HIV-1 integration are marked cDNA and IP, respectively. The positions of
molecular mass standards in kb are indicated to the right of the blot. An
ethidium stain of the agarose gel used for Southern blotting is shown in lanes
5–8. The 9 Ag of fX174 target DNA utilized in salt-stripped PIC integration
reactions resulted in somewhat retarded DNA mobilities in lanes 3, 4, 7, and
8 relative to lanes 1, 2, 5, and 6, respectively.of viral cDNA present in the different samples. Integration
activity after reconstitution was expressed as the percentage of
PIC function prior to salt depletion. LEDGF/p75 restored about
43% of the level of starting PIC activity in this experiment
(Fig. 2A); replicate measurements (n = 7) revealed LEDGF/
p75 displayed between 40% and 100% activity under these
assay conditions (data not shown). HRP2 restored about 39%
of starting integration activity under conditions where BAF and
RNase A restored approximately 15% and 2.4% of PIC
function, respectively (Fig. 2A).
LEDGF/p75 IN-binding and DNA-binding activities contribute
to functional PIC reconstitution
We next investigated LEDGF/p75 functions that might
contribute to PIC reconstitution activity. The protein contains
two evolutionarily-conserved subdomains, an N-terminal
PWWP domain (residues 1–93) and the IBD (residues 347–
429) (Cherepanov et al., 2004) (Fig. 2B). The IBD is necessary
but not sufficient to stimulate purified HIV-1 IN activity in
vitro (Cherepanov et al., 2004). LEDGF/p75 residue Asp-366
is essential for the interaction with IN, and full-length LEDGF/
p75 containing the D366N amino acid substitution displayed
approximately 8% of wild-type LEDGF/p75 activity in the IN
stimulation assay (Cherepanov et al., 2005; data not shown).
Purified LEDGF/p75 binds to DNA in vitro (Singh et al., 2001;
Busschots et al., 2005) and we recently determined that the
nuclear localization signal (NLS, residues 146–156; Fig. 2B)
and a dual copy of the AT-hook DNA-binding motif that spans
residues 178–197 mediates the binding of LEDGF/p75 to
DNA (F. Turlure, G. Maertens, P. Cherepanov, A. Engelman,
submitted for publication). Based on these observations, the
following purified LEDGF/p75 mutant proteins were tested:
347–471, which contains the IBD, binds IN, but does not
appreciably stimulate its activity (Cherepanov et al., 2004);
D366N, which fails to bind IN (Cherepanov et al., 2005); 1–
266, which lacks the IBD but retains DNA-binding activity
(submitted for publication); mutL1, which contains 12 amino
acid substitutions in the NLS and AT-hook motifs and displays
roughly 3% residual DNA-binding activity (submitted for
publication); and mutL1/D366N, which lacks both IN and
DNA-binding functions (Fig. 2B).
The 347–471 protein restored about 5.5% of starting PIC
function indicating that, akin to the result utilizing mini-HIV
substrate DNA (Cherepanov et al., 2004), IN-binding on its
own is insufficient to reconstitute significant salt-stripped PIC
activity (Fig. 2A). In contrast, the D366N missense mutant
displayed near-wild type activity in repeat experiments (32%
relative integration activity in Fig. 2A). Based on this, we
hypothesized that LEDGF/p75 DNA-binding activity was
likely to contribute to its functional PIC reconstitution activity.
As 1–266 restored only about 8% of starting PIC function (Fig.
2A), DNA-binding in the absence of IN-binding could only
marginally restore PIC function. Full-length mutL1 retained
about 40% of wild-type LEDGF/p75 function, indicating that
DNA-binding played a modest role in LEDGF/p75 function
under conditions where the wild-type affinity for IN is
Fig. 2. Reconstitution of salt-stripped PIC activity using LEDGF/p75, HRP2, BAF, RNase A, and LEDGF/p75 mutant proteins. (A) Starting, level of PIC activity
prior to salt-stripping, normalized to level of HIV-1 cDNA substrate. Mock, level of integration activity following incubation with BGF buffer alone. LEDGF/p75
was observed to reconstitute 2- to 3-fold more activity than BAF following three independent sets of HIV-1 infection, PIC isolation, and salt-stripping experiments.
Error bars indicate variation obtained following duplicate RQ-PCR assays. Similar results were obtained following independent sets of salt-stripping and
reconstitution assays. (B) Schematic diagram of LEDGF/p75, highlighting functional domains. The DNA-binding mutant protein mutL1 carries 6 amino acid
substitutions in the NLS as well as the substitutions of Ala–Ala–Ala for the invariant Arg–Gly–Arg sequences that comprise the heart of the AT-hook DNA-
binding motif (Reeves, 2001).
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mutant failed to appreciably reconstitute PIC function (about
3% relative integration activity), we conclude that DNA-
binding and IN-binding play synergistic roles in LEDGF/p75
PIC reconstitution activity (Fig. 2A).
Reducing intracellular levels of LEDGF/p75 does not
appreciably affect HIV-1 infectivity
To address the roles of LEDGF/p75 and HRP2 in HIV-1
replication, protein levels in HeLa-P4 cells (Charneau et al.,
1992) were reduced using transient delivery of siRNA prior to
infection with replication-competent HIV-1IIIB. This CD4-
positive indicator line was chosen because the cells (i) were
readily transfectable with siRNA and (ii) contain an integrated
h-galactosidase reporter gene under the control of the Tat-
responsive viral U3 promoter. This latter trait afforded a
convenient and quantitative screen for HIV-1 infectivity,
which was assessed following in situ staining with 5-bromo-4-chloro-3-indolyl-b-d-galactoside (Kimpton and
Emerman, 1992).
Eight siRNAs that targeted different regions of LEDGF/p75
were screened for their potential to suppress mRNA. Cells
transfected on 2 successive days were lysed 72 h after the first
transfection, and LEDGF/p75 levels were measured by
quantitative (q) RT-PCR. Two previously-described siRNAs,
L3 (Maertens et al., 2003) and 21 [based on a shRNA
expression vector (Devroe and Silver, 2002)] (Fig. 3A),
reduced LEDGF/p75 mRNA approximately 27- and 14-fold,
respectively (Fig. 3B). Co-transfection of 21 and L3 siRNAs
did not increase the knock-down beyond that observed with L3
siRNA alone (Fig. 3B, 21/L3).
Llano et al. (2004b) previously-described 293T and Jurkat
cell-based lines that stably express short-hairpin (sh) RNA and
potently down-regulate LEDGF/p75 expression. Normalized
levels of total input RNA was analyzed in side-by-side qRT-
PCR assays to compare the extent of LEDGF/p75 down-
regulation in these cells versus that achieved with the transient
Fig. 3. siRNA design and knock-down of LEDGF/p75. (A) Sense-strand
sequences, starting nucleotide (ntd), and relative positions of L3 and 21 siRNAs
and matched controls (L3C and 21C) along the LEDGF/p75 coding sequence
(CDS). Nucleotides in the matched controls that differed from L3 and 21 are in
bold and underlined. Relative positions of the alternative splice variant
LEDGF/p52, the conserved PWWP domain, and the IBD are shown; numbers
atop the CDS indicate amino acid position. (B) Relative LEDGF/p75 mRNA
levels following transfection of HeLa-P4 cells with the indicated siRNAs at 5
nM. The 21/L3 sample contained 10 nM total siRNA. Previously-described
si1340, si1340/1428, siScram (derived from 293T cells), and si1340JK Jurkat
cells (Llano et al., 2004b) were included for comparison. The JurkatBC cell line
expressed shRNA-resistant LEDGF/p75 in addition to si1340 shRNA (Llano et
al., 2004b). Error bars indicate variance obtained in duplicate qRT-PCR assays.
Similar results were obtained following an independent set of RNA isolation
and qRT-PCR assays. (C) LEDGF/p75 protein levels at 72 h post-transfection
with the indicated concentrations of siRNA. Blotting for CDK4 confirmed that
similar levels of total cell protein (10 Ag) were analyzed across samples. (D)
Semi-quantitative western analysis of the L3 siRNA-specific knock-down.
Numbers above lanes 1–4 are siRNA concentrations in nM.
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mRNA down-regulation in 293T-based si1340 cells was
approximately 12-fold, si1340/1428 cells, which expressedtwo different targeting shRNAs, harbored about 17-fold less
LEDGF/p75 message than parental 293T cells (Fig. 3B).
Control siScram cells, which expressed a non-targeting shRNA,
contained a normal level of LEDGF/p75 mRNA (Fig. 3B).
Whereas the level of LEDGF/p75 message in si1340JK cells
was reduced about 4.4-fold, a derivative of this cell line
engineered to express a shRNA-resistant form of LEDGF/p75
contained about 3-fold more message than parental Jurkat cells
(Fig. 3B). We note that si1340 shRNAwas based on L3 siRNA
and si1428 shRNA overlapped with the 21 siRNA used here
(identical stretch of 16 nucleotides). Given the caveats that
siRNAwas used in HeLa-P4 cells and shRNAwas expressed in
293T and Jurkat cells, we concluded that on average, siRNA
was approximately 1.6-fold more effective than shRNA at
reducing LEDGF/p75 mRNA levels (Fig. 3B).
Reducing siRNA concentration from 5 nM to 1 nM revealed
undetectable and barely detectable levels of LEDGF/p75
protein in cells transfected with L3 and 21 siRNAs, respec-
tively (Fig. 3C). As observed at the mRNA level, control
siRNAs yielded negligible effects on LEDGF/p75 protein
levels (Figs. 3B–D). Semi-quantitative western blotting
revealed that L3 siRNA mediated at least an 8-fold reduction
in the steady-state level of LEDGF/p75 protein (Fig. 3D).
Mock- and siRNA-transfected cells cultured with HIV-1IIIB
for 36 h were stained for h-galactosidase expression, and the
resulting blue cells were counted by light microscopy. Cells
transfected with either 21 or 21C siRNA supported levels of
HIV-1 infectivity that were nearly-identical to mock-treated
cells (Fig. 4A). Likewise, cells treated with 1 nM or 5 nM of
L3 siRNA did not reveal any appreciable affect on the level of
HIV-1 infection. In contrast, cells transfected with 40 nM L3
siRNA reproducibly supported 2- to 3-fold less infection than
control cells (Fig. 4A and data not shown). Similar results were
obtained when single-round HIV-1NL4–3 was used in place of
replication-competent HIV-1IIIB (data not shown), indicating
that results were independent of the viral strain or source of
virus (transiently-transfected 293T cell supernatant in the case
of single round HIV-1NL4–3 versus supernatant of chronically-
infected MOLTIIIB T-cells).
Because (i) cells transfected with 21 siRNA supported near-
wild type levels of infection (Fig. 4A) and (ii) the level of
LEDGF/p75 knock-down appeared similar in cells transfected
with L3 siRNA at 40 nM or 5 nM (Fig. 3D), we were
concerned that the infectivity defect in cells transfected with 40
nM L3 siRNA could be caused by affects unrelated to the
reduction in LEDGF/p75 protein. To assess the fitness of cells
under different conditions of siRNA treatment, parallel cultures
of cells utilized in Fig. 4A were analyzed for their proliferative
capacity using a commercially-available kit. Cells treated with
L3 siRNA at 40 nM were approximately 2.4-fold reduced in
their capacity to proliferate as compared to mock-transfected
cells (Fig. 4B). Similar results were observed using either
trypan blue staining or a second commercially-available kit that
measured cell viability (data not shown). We noted that the
proliferative status of cell cultures closely mirrored the level at
which they supported HIV-1 infection (compare Fig. 4B to A).
Together with the observations that 40 nM and 5 nM L3 siRNA
Fig. 4. HIV-1 infectivity and proliferative status of siRNA-treated cells. (A)
Infectivity was quantified by averaging the total number of blue cells in
quadruplicate cultures 36 h post-infection (p.i.) with HIV-1IIIB. (B) Cell
proliferation was assessed at 24 h p.i. M, mock.
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that an infectivity defect was not seen in cells treated with 21
siRNA despite effective knock-down of LEDGF/p75 protein
(Figs. 3C, 4A, and data not shown), the proliferation data
indicated that reductions in infectivity were more likely due to
decreased cell fitness rather than to the specific depletion of
LEDGF/p75 from cells.
Wild type levels of HIV-1 infection in cells reduced for both
LEDGF/p75 and HRP2
We recently determined that HRP2 was a second member of
the HDGF family of proteins that contained an IBD and
potently stimulated the in vitro integration activity of recom-
binant HIV-1 IN (Cherepanov et al., 2004). Because cells
depleted for LEDGF/p75 using shRNA vectors (Llano et al.,
2004b) or chemically-synthesized siRNA (Figs. 3B–D and
4A) supported near-wild type levels of HIV-1 infection, one
hypothesis was that HRP2 effectively played the role of
LEDGF/p75 in LEDGF/p75-depleted cells (Cherepanov et al.,
2004). To experimentally address this hypothesis, siRNAs were
screened for their ability to reduce intracellular HRP2 levels.
Of thirteen siRNAs tested by qRT-PCR, only two significantly
reduced HRP2. Of these, Dh4 siRNA (Fig. 5A) was the least
cytotoxic (data not shown) and therefore was used in
subsequent experiments. HRP2 mRNA was reduced approxi-mately 12-fold in HeLa-P4 cells transfected with Dh4 siRNA at
three different concentrations although notably, control Dh4C3
siRNA at 40 nM also moderately reduced the message (Fig.
5B). Consistent with this observation, Dh4 and Dh4C3 siRNAs
negatively-impacted cell viability and proliferation when either
was used at 40 nM (data not shown). Subsequent experiments
therefore utilized Dh4 siRNA at 5 nM.
Because an anti-HRP2 antibody was not available, the
potential for Dh4 siRNA to knock-down HRP2 protein levels
was assessed by co-transfecting siRNAs with a haemagglutinin
(HA)-tagged HRP2 expression vector (Cherepanov et al.,
2004). Previous analyses of HA-HRP2 expression in human
293T cells revealed that it migrated significantly more slowly
in sodium dodecyl sulfate (SDS)-polyacrylamide gels than
recombinant HRP2 protein (Cherepanov et al., 2004), indicat-
ing that HRP2 might undergo post-translational modification in
animal cells. Analysis of the HRP2 protein sequence using the
NetPhos 2.0 Server (Blom et al., 1999) revealed numerous
potential sites of Ser, Tyr, and Thr phosphorylation and because
of this, the migration pattern of HA-HRP2 was investigated
following treatment with calf intestinal phosphatase (CIP).
Because the electrophoretic mobility of HA-HRP2 shifted after
CIP treatment, we concluded that the protein was indeed
phosphorylated in human cells (Fig. 5C). HA-HRP2-containing
lysates were subsequently treated with CIP prior to electro-
phoresis and Western blotting.
Co-transfecting Dh4 siRNA with the HA-HRP2 expression
vector ablated HRP2 detection (Fig. 5D, lane 1), indicating that
Dh4 siRNA likely reduced intracellular levels of endogenous
HRP2 protein. Of note, HA-HRP2 was efficiently expressed
following co-transfection with each of the Dh4-matched
control siRNAs (Fig. 5D, lanes 2–4).
HIV-1IIIB infectivity was assessed in HeLa-P4 cells trans-
fected with Dh4 siRNA or L3 siRNA alone, in combination, or
with matched control siRNAs. Neither Dh4 siRNA nor L3
siRNA negatively impacted cell proliferation (Fig. 6A) or
viability (not shown) when used separately at 5 nM or in
combination (10 nM total siRNA). Following co-transfection
with Dh4 and L3 siRNAs, HRP2 and LEDGF/p75 mRNAs
were reduced to levels similar to those observed following
treatment with individual siRNAs (Figs. 3B, 5B, and data not
shown). HIV-1 infectivity was not significantly altered in
HeLa-P4 cells transfected with Dh4 siRNA or co-transfected
with Dh4 and L3 siRNAs versus cells transfected with matched
control siRNAs (Fig. 6B). Of note, HRP2 and LEDGF/p75
mRNA levels remained suppressed during the course of HIV-1
infection (data not shown).
Discussion
Efficient reconstitution of HIV-1 PIC activity with purified
LEDGF/p75 or HRP2 protein
Previous experiments established that LEDGF/p75 was a
dominant cellular binding partner of HIV-1 IN when the virus
protein was expressed on its own in human cells (Cherepanov
et al., 2003; Llano et al., 2004a, 2004b; Maertens et al., 2003,
N. Vandegraaff et al. / Virology 346 (2006) 415–426 4212004; Turlure et al., 2004). Consistent with a potential role for
the IN-LEDGF/p75 interaction in HIV-1 biology, LEDGF/p75
was found to associate with HIV-1 PICs (Llano et al., 2004b).
Treating HIV-1 PICs with relatively high concentrations of salt
was previously shown to ablate their in vitro integration
activity, and extracts of uninfected T-cells restored function to
salt-depleted PICs (Chen and Engelman, 1998; Farnet and
Bushman, 1997). These observations were some of the first to
indicate that host cell proteins likely played important roles in
HIV-1 integration (reviewed in Engelman, 2003; Turlure et al.,
2004). LEDGF/p75 and HRP2 potently stimulated the in vitro
integration activity of recombinant HIV-1 IN protein (Cher-
epanov et al., 2003; 2004), but neither protein was previouslyFig. 5. HRP2 knock-down via siRNA. (A) Sense-strand sequence, starting
nucleotide (ntd), and relative position of Dh4 siRNA and matched controls
(Dh4C1, Dh4C2, and Dh4C3) along the HRP2 coding sequence (CDS).
Nucleotides in control sequences that differed from Dh4 siRNA are bold and
underlined. The PWWP domain and IBD are indicated. (B) Relative HRP2
mRNA levels following transfection of the indicated siRNAs at 40 nM, 5 nM,
or 1 nM. Duplicate RNA samples harvested at 48 h post-transfection were
analyzed by qRT-PCR. (C) HA-HRP2 is phosphorylated in vivo. Lysates were
either treated (+) with CIP or left untreated () prior to electrophoresis of 1 Ag
or 200 ng of total cell protein, as indicated. The migration positions of
molecular mass standards in kDa are indicated to the right of the gel. (D) HA-
HRP2 protein levels following co-transfection with siRNA. Total cell protein
recovered 36 h after co-transfecting cells with the pCPHA-HRP2 expression
vector and either Dh4 siRNA (lane 1) or indicated matched control siRNAs
(lanes 2–4). Control transfections included pCDNA6 (the plasmid from which
pCPHA-HRP2 was derived; lane 5) and pCPHA-HRP2 without added siRNA
(lane 6). Migration positions of molecular mass standards in kDa are indicated
to the right.
Fig. 6. Proliferative and infectivity statuses of cells following treatment with
different siRNAs. (A) Cell proliferation was quantified 24 h p.i. with the
indicated siRNAs. (B) Average numbers of blue cell counts were determined in
quadruplicate cultures 36 h p.i. with HIV-1IIIB.tested for its ability to restore function to salt-depleted HIV-1
PICs. Here, we show that purified LEDGF/p75 protein
functions quite efficiently in this assay. LEDGF/p75 could
restore integration activity to a level similar to that present prior
to salt-stripping (Fig. 1 and data not shown). Similar analyses
using HMGA1 (Farnet and Bushman, 1997) and BAF (Chen
and Engelman, 1998) reported reconstitution of approximately
50% of initial PIC function by each of these factors, indicating
that LEDGF/p75 is particularly active under these assay
conditions. Mutational analyses revealed that both the IN-
Fig. 7. Estimation of the LEDGF/p75 copy number in HeLa-P4 cells. Duplicate
supernatant (S) and pellet (P) fractions from 3  104 cells were analyzed by
Western blotting alongside a 5-fold dilution series of recombinant LEDGF/p75
protein. Densitometric scanning revealed approximately 1.2 ng of LEDGF/p75
in each of the first two lanes, which, based on a molecular mass of 60,103 Da
(Cherepanov et al., 2005), equated to approximately 400,645 protein molecules
per cell.
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uted to its activity in the PIC reconstitution assay (Fig. 2).
Normal levels of HIV-1 infection in cells depleted for
LEDGF/p75 and/or HRP2
Despite the mass of biochemical data implicating a role for
LEDGF/p75 in HIV-1 replication, previous attempts to reduce
the intracellular level of LEDGF/p75 protein using shRNA
vectors failed to ascribe a genetic link between endogenous
levels of LEDGF/p75 protein and HIV-1 infection (Llano et
al., 2004b). The IBD in LEDGF/p75 was subsequently
determined to reside in another protein, HRP2 (Cherepanov
et al., 2004). We therefore envisioned two mutually non-
exclusive reasons for why HIV-1 replicated in cells knocked-
down for LEDGF/p75 expression: (i) residual levels of
endogenous LEDGF/p75 protein within these cells were
sufficient to support wild type levels of integration and/or
(ii) replacement of LEDGF/p75 function by the IBD-contain-
ing HRP2.
To address these hypotheses, HeLa-P4 cells were subjected
to transient delivery of siRNA. Cells containing approximate
27-fold and 10-fold reductions in LEDGF/p75 mRNA and
protein, respectively (Figs. 3B, C, and D), supported normal
levels of HIV-1 infection (Fig. 4A). When L3 siRNAwas used
at 40 nM, however, we routinely observed 2- to 3-fold
reductions in HIV-1 infectivity (Fig. 4A). This effect was not
recapitulated using L3 siRNA at 5 nM or 21 siRNA at 5 nM or
40 nM, even though these treatments likewise elicited potent
reductions in LEDGF/p75 message and protein (Figs. 3B–D
and data not shown). Side-by-side infectivity and cell
proliferation measurements indicated that the infection defect
observed at 40 nM L3 siRNA was likely due to an impaired
ability for the transfected cells to grow (Fig. 4). These
observations highlight the need to confirm biological pheno-
types with multiple siRNAs, as previously recommended
(Anonymous, 2003; Huppi et al., 2005; Jackson et al., 2003;
Jackson and Linsley, 2004). Our findings agree with those of
Llano et al. (2004b) who reported that 293T and Jurkat cells
harboring reduced levels of LEDGF/p75 protein supported
normal levels of HIV-1 infection.
In terms of whether residual levels might suffice to support
wild type levels of HIV-1 integration, we note that HeLa-P4
cells harbor a relative abundance of LEDGF/p75 protein. Using
serial dilutions of purified LEDGF/p75 protein and semi-
quantitative western blotting, we estimated approximately 4 
105 molecules of LEDGF/p75 protein per cell (Fig. 7). Based
on this, we conclude that approximately 25,000 copies of
LEDGF/p75 are likely to persist under our most effective
knock-down conditions (Fig. 3D). Given the relatively high
affinity of IN for LEDGF/p75, which appears to be on the order
of 10 nM (P. Cherepanov and A. Engelman, unpublished
observations), we speculate that relatively high residual levels
of LEDGF/p75 might function to support normal levels of
HIV-1 integration. Given the limitations of RNAi technologies
to erase residual levels of target proteins from cells, the
relatively high copy number of LEDGF/p75 protein insusceptible target cells, and the relatively strong interaction
between LEDGF/p75 and HIV-1 IN, we propose that genetic
knock-out cell lines will be required to unequivocally address
the role of LEDGF/p75 in HIV-1 replication.
To investigate the hypothesis that HRP2 might provide an
important function for HIV-1 in cells harboring reduced levels
of LEDGF/p75, HRP2 was targeted by siRNA (Fig. 5A). Cells
containing approximately 12-fold less HRP2 mRNA than
control cells (Fig. 5B) supported near wild type levels of
HIV-1 infectivity (Fig. 6B). Normal levels of HIV-1 infection
were also observed in cells reduced for both HRP2 and
LEDGF/p75 (Fig. 6B). Because an antibody against HRP2 was
unavailable, our findings must be interpreted with the
limitation that we were unable to measure any potential
reduction in endogenous HRP2 protein upon siRNA treatment.
We did however demonstrate significant reductions in ectop-
ically-expressed HA-HRP2 upon cotransfection with Dh4
siRNA (Fig. 5D).
Our results with HRP2 are perhaps not all that surprising in
light of recent findings that ectopically-expressed HRP2
yielded a pattern of intra-nuclear localization that differed
from LEDGF/p75 (Vanegas et al., 2005). Whereas LEDGF/
p75 tightly associated with chromatin (Cherepanov et al.,
2003; Emiliani et al., 2005; Maertens et al., 2003; Nishizawa
et al., 2001; Vanegas et al., 2005), HRP2 appeared diffuse
throughout the nucleus and did not strongly associate with
DNA. Furthermore, the relative affinity of the HRP2-IN
interaction in human cells appeared to be much lower than
the LEDGF/p75-IN interaction (Cherepanov et al., 2004;
Vanegas et al., 2005). Although these findings do not discount
a role for HRP2 in the early events of HIV-1 replication, the
close association of LEDGF/p75 with chromatin and the
relative strength of the IN-LEDGF/p75 interaction suggest that
LEDGF/p75 is more likely than HRP2 to play a role in HIV-1
integration/replication.
Because of the inability of RNAi technology to completely
erase targeted gene products from cells, we have initiated
projects to genetically ablate LEDGF/p75 and HRP2 from
cells. Until these reagents become available, it may prove
difficult to ascertain by genetic means whether the plethora of
encouraging biochemical data for these host factors translates
to clear biological roles in HIV-1 replication.
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Expression plasmids and recombinant proteins
Vectors for expressing HA-tagged and untagged HRP2 in
animal and bacterial cells, respectively, were previously
described (Cherepanov et al., 2004). Recombinant LEDGF/
p75 protein with an N-terminal His6-tag was expressed in
Escherichia coli from pFT-1-LEDGF, which was derived from
pRSETB (Invitrogen Corp.) by amplifying LEDGF/p75
sequences from pCP-Nat75 (Maertens et al., 2003) with
Bgl II-tagged 5V-GCGCAGATCTCTGGAAGTTCTGT
TCCAGGGGCCCGGATCCATCACTCGCGATTTCAAAC-
CTGGAGACC and EcoRI-tagged 5V-CGCGAATTCCTAGTT-
ATCTAGTGTAGAATCC (restriction enzyme sites underlined)
using PfuUltra DNA polymerase (Stratagene) under conditions
recommended by the manufacturer. The bold bases in the
BglII-tagged primer encode for LEVLFQGP, which is the
recognition site for PreScission Protease (Amersham Bios-
ciences Corp.). Amplified DNA digested with BglII and EcoRI
was ligated with BamHI/EcoRI-digested pRSETB.
Cells harboring pFT-1-LEDGF were grown at 32 -C to an
optical density of 0.8–0.9 at 600 nm, at which time isopropyl-
thio-h-d-galactopyranoside was added to the final concentra-
tion of 0.5 mM. Cells grown for an additional 4 h at 28 -C were
harvested, frozen at 80 -C, and thawed cells were lysed in
buffer A [1 M NaCl, 25 mM Tris–HCl pH 7.4, 0.5 mM
phenylmethylsulfonyl fluoride (PMSF), 15 mM imidazole,
EDTA-free Complete protease inhibitor (Roche Diagnostics)].
Sonicated lysates clarified by centrifugation were incubated
with Ni-NTA agarose beads (QIAGEN) for 1 h at 4 -C, and
bound proteins were eluted in buffer A containing 200 mM
imidazole. LEDGF/p75-containing fractions were pooled and
the His-tag was removed by incubating overnight at 4 -C with
4 U of PreScission Protease (Amersham Biosciences Corp.) per
mg of protein. Cleaved LEDGF/p75 diluted 5-fold with 50 mM
NaH2PO4, pH 7.2 (to reduce the NaCl concentration to 200
mM) was loaded onto a HiTrap SP Sepharose column
(Amersham Biosciences Corp.) and was eluted with a linear
gradient of NaCl from 0.2 to 1 M in 50 mM NaH2PO4 pH 7.2.
Pooled LEDGF/p75-containing fractions were further purified
by gel filtration using a Superdex 200 column (Amersham
Biosciences Corp.) in 120 mM NaCl, 25 mM Tris–HCl pH
7.4. LEDGF/p75-containing fractions were pooled, concentrat-
ed using a Centricon-10 concentrator (Millipore Corp.),
supplemented with glycerol to 10% (wt/vol), flash frozen in
liquid N2, and stored at 80 -C. Protein concentrations were
determined using the Bio-Rad protein assay kit (Bio-Rad
Laboratories).
HRP2, the LEDGF/p75 IBD (residues 347–471), and
LEDGF/D366N were purified as previously described (Cher-
epanov et al., 2004, 2005). The 1–266 deletion mutant
expressed as a fusion to glutathione S-transferase from
pGEX-6P3 (Amersham Biosciences Corp.) was purified
essentially as described for previous LEDGF/p75 deletion
mutant proteins (Cherepanov et al., 2004). The GST tag was
removed by cleavage with PreScission Protease as outlinedabove. The mutL1 protein, expressed from a pFT-1-LEDGF-
based vector, was purified as described above for wild-type
LEDGF/p75.
Human BAF was purified following its expression in
bacteria essentially as previously described (Harris and Engel-
man, 2000) with the addition that re-folded BAF dimers were
purified by gel filtration on a Superdex 200 column operated in
BGF buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 0.1 mM
EDTA, 50 mM h-mercaptoethanol, 10% [wt/vol] glycerol).
RNase A was from QIAGEN.
PIC isolation, salt-stripping, and integration assays
PICs isolated at 7 h p.i. from cytoplasmic extracts of
MOLTIIIB and SupT1 cell co-cultures as described (Chen et
al., 1999) were adjusted to contain 7% sucrose (wt/vol), snap-
frozen in liquid N2, and stored at 80 -C. Salt-stripping was
performed essentially as previously described (Brooun et al.,
2001; Chen and Engelman, 1998). Briefly, samples (700 Al) in
isotonic buffer K (20 mM HEPES pH 7.5, 5 mM MgCl2, 150
mM KCl, 1 mM dithiothreitol [DTT], 20 Ag/ml aprotinin,
0.025% [wt/vol] digitonin) were thawed on ice and incubated
with an equal volume of no-salt buffer K (20 mM HEPES pH
7.5, 5 mM MgCl2, 1 mM DTT) for 30 min on ice before
centrifuging at 8000  g for 20 min at 4 -C. Pelleted material
resuspended in 700 Al of high-salt buffer K (20 mM HEPES
pH 7.5, 5 mM MgCl2, 1.2 M KCl, 1 mM DTT) was incubated
on ice for 30 min. High salt-treated PICs were partially purified
by Sepharose CL-4B (Amersham Biosciences Corp.) spin
column chromatography (Chen et al., 1999). Eluate concentrat-
ed to approximately 87.5 Al by centrifugation in a Microcon-100
ultrafiltration unit (Millipore Corp.) at 14,000  g was
readjusted to isotonic salt concentration by adding 612.5 Al of
no-salt buffer K. For reconstitution, purified proteins (800 nM
final) diluted into 20 Al of BGF buffer were incubated with 180
Al salt-stripped PICs in the presence of 0.1 mg/ml bovine serum
albumin for 1 h on ice. Reconstitution assays were scaled-up for
Southern blotting to a final volume of 3 ml. Integration into
fX174 target DNA (3 Ag/ml) proceeded for 45min at 37 -C, and
integration activity was quantified by PhosphorImager using
ImageQuant version 1.2 as the percent of total HIV-1 cDNA
converted to product.
For RQ-PCR-based PIC assays, plasmid pTZ18U/PL (3 Ag/
ml) was utilized instead of fX174 as an integration target.
Primers and cycling parameters were the same as in Lu et al.
(2005b) with the exception that 23 cycles were utilized in first
round reactions. Percent functional reconstitution was defined
as the level of integration activity as compared to starting PICs
(180 Al + 20 Al BGF buffer). Activities of reconstituted versus
starting samples were normalized to the total levels of HIV-1
cDNA in the different samples, as described (Lu et al., 2005b).
Cell lines
HeLa-P4 cells (Charneau et al., 1992) and 293T cells were
cultured in Dulbecco’s modified Eagle Medium containing
10% fetal bovine serum, 100 IU/ml penicillin, and 100 Ag/ml
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Jurkat T-cells (Weiss et al., 1984), and chronically-infected
MOLTIIIB T-cells (Farnet and Haseltine, 1990) were cultured
in RPMI 1640 media containing 10% fetal bovine serum, 100
IU/ml penicillin, and 100 Ag/ml streptomycin (RPMI).
A number of cell lines expressing shRNA were a generous
gift from Dr. Eric Poeschla (Mayo Clinic, Rochester, Minne-
sota). si1340 and siScram cells, derived from 293T cells, were
grown in DMEM containing hygromycin B (200 Ag/ml); the
media for 293T-based siL1340/1428 cells additionally
contained puromycin at 3 Ag/ml. JurkatBC and si1340JK cells,
derived from Jurkat T-cells, were grown in RPMI containing
800 Ag/ml hygromycin B.
Viruses and infections
Replication-competent HIV-1IIIB collected from high-densi-
ty cultures of MOLTIIIB cells was passed through a 0.45-Am
filter and stored at 80 -C. Single-round viruses carrying HIV-
1NL4-3 envelope glycoproteins were derived by co-transfecting
293T cells with pNLX.Luc(R-) and pNLXE7 at the ratio of
30:1 using calcium-phosphate as previously described (Lu et
al., 2005a; Sambrook et al., 1989). Culture supernatants
collected 48 h post-transfection were filtered prior to use. All
viruses were titered on HeLa-P4 cells essentially as previously
described (Engelman et al., 1995; Kimpton and Emerman,
1992). Cells (6.7  103/well) plated in 96 well plates 24
h before infection were stained for h-galactosidase activity
using standard protocols (Kimpton and Emerman, 1992)
between 36 h and 48 h p.i. Cell viability was assessed either
by trypan blue exclusion or the CellTiter-Blue Cell Viability
Assay (Promega Corp.). Cell proliferation was measured using
the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega Corp.).
Design, synthesis, and transfection of siRNAs
Double-stranded siRNAs were purchased from Dharmacon
Research. L3 (Maertens et al., 2003) and 21 [based on a
shRNA expression vector (Devroe and Silver, 2002)] were
previously-described LEDGF/p75-specific siRNAs. Whereas
the sense-strand sequence of L3 siRNAwas 5V-AGACAGCAU-
GAGGAAGCGAdTdT, the 21 sequence was 5V-GGUCAAA-
GACUCUAAAUGGAGdTdT. The following controls that
differed from antagonistic siRNAs by three internal base
changes were also utilized: L3C siRNA (5V-AGACAGCUU-
CACGAAGCGAdTdT; mutated bases underlined) and 21C
(5V-GGUCAAACAGUGUAAAUGGAGdTdT). The sense-
strand sequence of Dh4 siRNA targeting HRP2 was 5V-
CGACAAAUGUAAAGACAAGdTdT. In this case three dif-
ferent control siRNAs, containing three or four base changes,
were utilized: Dh4C1 (5V-CGACAAUUCUUAAGACAAGdT-
dT), Dh4C2 (5V-CGACAAUUCUUAUGACAAGdTdT), and
Dh4C3 (5V-CGACAAAAUGUAAGACAAGdTdT).
HeLa-P4 cells (2  105) plated in 6-well trays the day
before transfection were transfected twice on successive days
with indicated concentrations of siRNA using oligofectamine(Invitrogen) essentially as described by the manufacturer (see
http://www.invitrogen.com/content/sfs/protocols/sirna_oftsf_
proc.pdf). Cells were co-transfected just once with siRNA and
plasmid DNA using CaPO4.
Protein extraction and western blotting
Proteins were extracted on ice from HeLa-P4 cells for 15
min using RIPA buffer (20 mM HEPES pH 7.6, 150 mM NaCl,
1% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS, 2 mM
EDTA, complete protease inhibitor [Roche Diagnostics]), and
protein concentration was quantified using the Dc Protein
Assay (Bio-Rad Laboratories). LEDGF/p75 and cyclin-depen-
dent kinase 4 (CDK4, which served as a loading control) were
detected by western blotting as described (Devroe and Silver,
2002).
To determine the approximate LEDGF/p75 copy number in
HeLa-P4 cells, duplicate samples (2  106 cells) following
extraction with RIPA buffer were centrifuged, and 10 Ag of
total protein in supernatant fractions (equating to 3  104 cells)
were compared by Western blotting alongside a matched
volume of pelleted fractions resuspended in protein sample
buffer and a 5-fold dilution series of recombinant LEDGF/p75
protein. Quantitation was performed using Quantify One
version 4.1.1 software (Bio-Rad Laboratories).
Lysates containing HA-HRP2 were treated with 5 U of CIP
(New England Biolabs Inc.) for 15 min at 30 -C before loading
onto 6% Tris-glycine gels (Invitrogen). Proteins transferred to
polyvinylidene difluoride membrane using a Trans-Blot SD
Semi-Dry Transfer Cell apparatus (Bio-Rad Laboratories) were
detected using anti-HA.11 clone 16B12 antibody (Covance
Research Products, Inc.) and the ECL Plus Western Blotting kit
(Amersham Biosciences Corp.).
RNA extraction and qRT-PCR
RNA extracted from cells using the RNeasy Mini Kit
(QIAGEN) was quantified by spectrophotometry. Primers for
qRT-PCR were designed to span intron/exon boundaries.
Primers for amplifying cyclophilin A (CypA) were:
5V-TTCATCTGCACTGCCAAGAC and 5V-TGGTCTTGCCAQ
TTCCTGGAC. LEDGF/p75-specific primers were 5V-AAGC-
TAGAGAAGGAACAAAC and 5V-TTGCTGTCTTCATTGC-
TCTC and HRP2 primers were 5V-AAGTTTGCCCTAAAGGTQ
CGAC and 5V-GCTTTGTAACGGCGAATCT.
Semi-quantitative standard curves were constructed by
analyzing 5-fold dilutions of RNA (from 25 ng to 0.04 ng)
extracted from mock-transfected cells or parental cell lines.
PCR was performed with the QuantiTect SYBR Green RT-PCR
kit (QIAGEN) using either 5 ng (for CypA) or 25 ng (LEDGF/
p75 and HRP2) of template RNA in a final volume of 30
Al under conditions recommended by the manufacturer.
Reactions conducted in a DNA Engine Opticon thermal cycler
(MJ Research Inc.) were: 50 -C for 30 min, 95 -C for 15 min,
followed by 40 cycles of 94 -C for 15 s, 55 -C for 30 s and 72
-C for 30 s. Melting curve analyses (from 55 -C to 90 -C, read
every 1 -C) were conducted to verify that each primer pair
N. Vandegraaff et al. / Virology 346 (2006) 415–426 425predominantly amplified a single DNA species. Values of
unknown samples were normalized to the CypA content of
RNA extracts using the OpticonMONITOR Analysis Software
version 2.01 supplied by the manufacturer.
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